keyword
MENU ▼
Read by QxMD icon Read
search

poor ovarian response

keyword
https://www.readbyqxmd.com/read/29774110/high-throughput-3-dimensional-culture-of-epithelial-ovarian-cancer-cells-as-preclinical-model-of-disease
#1
Victoria Heredia-Soto, Andrés Redondo, Alberto Berjón, María Miguel-Martín, Esther Díaz, Roberto Crespo, Alicia Hernández, Laura Yébenes, Alejandro Gallego, Jaime Feliu, David Hardisson, Marta Mendiola
Background: Recent reports have identified distinct genomic patterns in ovarian carcinoma, including proliferative and mesenchymal-like groups, with worse outcome. The exact mechanisms driving the onset and progression of these tumors are still poorly understood. Additionally, researchers are concerned about the correct subtype stratification of the available cell line models, and the exploration of alternatives to monolayer culture. Identification of biomarkers to stratify cell lines, characterization of important processes as epithelial-mesenchymal transition (EMT), and the use of three-dimensional (3D) cultures as alternative models could be useful for cell line classification...
April 24, 2018: Oncotarget
https://www.readbyqxmd.com/read/29767464/platinum-resistant-recurrent-ovarian-cancer-with-long-survival-on-bevacizumab-and-gemcitabine
#2
Shinichi Komiyama, Tsuyoki Kugimiya, Chiaki Takeya, Rena Takahashi, Kaneyuki Kubushiro
Platinum-resistant recurrent ovarian cancer has a poor prognosis, but combined therapy with bevacizumab and anticancer agents may be useful. We report a patient with long-term disease control by the combination of bevacizumab and gemcitabine (BEV + GEM). The patient was a 77-year-old woman with high-grade Stage IIIC serous ovarian carcinoma. In 2012, a complete response (CR) was obtained by neoadjuvant and adjuvant chemotherapy using paclitaxel plus carboplatin and tumor debulking surgery. After recurrence in 2013, CR was achieved again with gemcitabine plus carboplatin...
May 16, 2018: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/29750700/assessment-of-a-chemotherapy-response-score-crs-system-for-tubo-ovarian-high-grade-serous-carcinoma-hgsc
#3
Helena M Ditzel, Kyle C Strickland, Emily E Meserve, Elizabeth Stover, Panagiotis A Konstantinopoulos, Ursula A Matulonis, Michael G Muto, Joyce F Liu, Colleen Feltmate, Neil Horowitz, Ross S Berkowitz, Mamta Gupta, Jonathan L Hecht, Douglas I Lin, Kirsten M Jochumsen, William R Welch, Michelle S Hirsch, Bradley J Quade, Kenneth R Lee, Christopher P Crum, George L Mutter, Marisa R Nucci, Brooke E Howitt
A chemotherapy response score (CRS) system was recently described to assess the histopathologic response and prognosis of patients with tubo-ovarian high-grade serous carcinoma (HGSC) receiving neoadjuvant chemotherapy. The current study was performed as an independent assessment of this CRS system. We retrospectively identified advanced stage HGSC patients who received neoadjuvant chemotherapy and underwent interval debulking. If available, a hemotoxylin and eosin slide from the omentum and the adnexa was selected for the study...
May 10, 2018: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/29743597/mastl-overexpression-promotes-chromosome-instability-and-metastasis-in-breast-cancer
#4
Samuel Rogers, Rachael A McCloy, Benjamin L Parker, David Gallego-Ortega, Andrew M K Law, Venessa T Chin, James R W Conway, Dirk Fey, Ewan K A Millar, Sandra O'Toole, Niantao Deng, Alexander Swarbrick, Paul D Chastain, Anthony J Cesare, Paul Timpson, C Elizabeth Caldon, David R Croucher, David E James, D Neil Watkins, Andrew Burgess
MASTL kinase is essential for correct progression through mitosis, with loss of MASTL causing chromosome segregation errors, mitotic collapse and failure of cytokinesis. However, in cancer MASTL is most commonly amplified and overexpressed. This correlates with increased chromosome instability in breast cancer and poor patient survival in breast, ovarian and lung cancer. Global phosphoproteomic analysis of immortalised breast MCF10A cells engineered to overexpressed MASTL revealed disruption to desmosomes, actin cytoskeleton, PI3K/AKT/mTOR and p38 stress kinase signalling pathways...
May 10, 2018: Oncogene
https://www.readbyqxmd.com/read/29742518/immune-checkpoint-inhibitors-in-the-treatment-of-patients-with-neuroendocrine-neoplasia
#5
Matthias M Weber, Christian Fottner
BACKGROUND: Well-differentiated neuroendocrine neoplasms (NENs) are usually controlled by antiproliferative, local ablative and/or radionuclide therapies, whereas poorly differentiated NENs generally require cytotoxic chemotherapy. However, treatment options for patients with advanced/metastatic high-grade NENs remain limited. METHOD: Review of the literature and international congress abstracts on the efficacy and safety of immunotherapy by checkpoint inhibition in advanced/metastatic NENs...
2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29725001/ablation-of-beta-subunit-of-protein-kinase-ck2-in-mouse-oocytes-causes-follicle-atresia-and-premature-ovarian-failure
#6
Qiu-Xia Liang, Zhen-Bo Wang, Fei Lin, Chun-Hui Zhang, Hong-Mei Sun, Liang Zhou, Qian Zhou, Heide Schatten, Filhol-Cochet Odile, Boldyreff Brigitte, Qing-Yuan Sun, Wei-Ping Qian
Premature ovarian failure (POF), a major cause of female infertility, is a complex disorder, but the molecular mechanisms underlying the disorder are only poorly understood. Here we report that protein kinase CK2 contributes to maintaining follicular survival through PI3K/AKT pathway and DNA damage response pathway. Targeted deletion of CK2β in mouse oocytes from the primordial follicle stage resulted in female infertility, which was attributed to POF incurring by massive follicle atresia. Downregulated PI3K/AKT signaling was found after CK2β deletion, indicated by reduced level of phosphorylated AKT (S473, T308, and S129) and altered AKT targets related to cell survival...
May 3, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29714649/personalized-therapy-based-on-sequential-molecular-analysis-leads-to-30-months-of-survival-in-a-patient-with-diffuse-unresectable-gastric-linitis-plastica
#7
Linda Mahjoubi, Fabiola Cecchi, Christophe Massard, Fabio Calabro, Anas Gazzah, Rastislav Bahleda, Philippe Jamme, Maximiliano Gelli, Diane Goere, Ludovic Lacroix, Julien Adam, Lukas Heukamp, Patrizia Trenta, Todd Hembrough, Jean-Charles Soria, Cora Sternberg, Michel Ducreux
INTRODUCTION: Diffuse gastric cancer is associated with poor prognosis. We report a patient with metastatic gastric linitis plastica harboring human epidermal growth factor receptor 2 ( HER2) activating mutation and HER2 amplification. CASE DESCRIPTION: The patient received 5-fluorouracil/folinic acid and oxaliplatin combined with trastuzumab/pertuzumab, resulting in disease control for 8 months. Second-line therapy with nivolumab and trastuzumab/pertuzumab was well-tolerated, with macroscopic peritoneal response...
March 1, 2018: Tumori
https://www.readbyqxmd.com/read/29704517/duoxa1-mediated-ros-production-promotes-cisplatin-resistance-by-activating-atr-chk1-pathway-in-ovarian-cancer
#8
Yunxiao Meng, Chi-Wei Chen, Mingo M H Yung, Wei Sun, Jing Sun, Zhuqing Li, Jing Li, Zongzhu Li, Wei Zhou, Stephanie S Liu, Annie N Y Cheung, Hextan Y S Ngan, John C Braisted, Yan Kai, Weiqun Peng, Alexandros Tzatsos, Yiliang Li, Zhijun Dai, Wei Zheng, David W Chan, Wenge Zhu
The acquisition of resistance is a major obstacle to the clinical use of platinum drugs for ovarian cancer treatment. Increase of DNA damage response is one of major mechanisms contributing to platinum-resistance. However, how DNA damage response is regulated in platinum-resistant ovarian cancer cells remains unclear. Using quantitative high throughput combinational screen (qHTCS) and RNA-sequencing (RNA-seq), we show that dual oxidase maturation factor 1 (DUOXA1) is overexpressed in platinum-resistant ovarian cancer cells, resulting in over production of reactive oxygen species (ROS)...
April 25, 2018: Cancer Letters
https://www.readbyqxmd.com/read/29703793/liraglutide-increases-ivf-pregnancy-rates-in-obese-pcos-women-with-poor-response-to-first-line-reproductive-treatments-a-pilot-randomized-study
#9
Vesna Salamun, Mojca Jensterle, Andrej Janez, Eda Vrtacnik Bokal
OBJECTIVE: Glucagon-like peptide-1 (GLP-1) has been investigated in regulation of reproductive system in animal models. The potential impact of short-term preconception intervention with liraglutide on fertility potential in PCOS has not been evaluated yet. DESIGN: A prospective randomized open-label study was conducted in 28 infertile obese PCOS patients (age 31.07±4.75 years, BMI 36.7±3.5 kg/m2, mean±SD). They were assigned to metformin (MET) 1000 mg BID or to MET 1000 mg BID combined with low-dose liraglutide 1...
April 27, 2018: European Journal of Endocrinology
https://www.readbyqxmd.com/read/29697414/the-dilemma-of-aneuploidy-screening-on-low-responders
#10
Scott J Morin, Daniel J Kaser, Jason M Franasiak
PURPOSE OF REVIEW: Preimplantation genetic testing for aneuploidy (PGT-A) has been demonstrated to improve implantation and pregnancy rates and decrease miscarriage rates over standard morphology-based embryo selection. However, there are limited data on its efficacy in patients with diminished ovarian reserve or a poor response to stimulation who may have fewer embryos to select amongst. RECENT FINDINGS: Early findings demonstrate that PGT-A reduces the miscarriage rate and decreases the time to delivery in poor responders...
April 24, 2018: Current Opinion in Obstetrics & Gynecology
https://www.readbyqxmd.com/read/29681712/effectiveness-of-anti-mullerian-hormone-tailored-protocol-compared-to-conventional-protocol-in-women-undergoing-in-vitro-fertilization-a-randomized-controlled-trial
#11
Sumi Thomas, Mousumi Acharya, K Muthukumar, Achamma Chandy, Mohan S Kamath, T K Aleyamma
Background: Assessment of ovarian reserve before an in vitro fertilization cycle (IVF) is one among the many factors that predicts a successful cycle. Individualized protocol based on ovarian reserve is designed to optimize the pregnancy outcome without compromising the patient safety. Although authors have shown that anti-Mullerian hormone-tailored (AMH) protocols have reduced the treatment burden and improved pregnancy rates, a few others have questioned its efficacy. Aims: The aim of this study was to decide whether the AMH-tailored protocol or the conventional protocol better decides IVF outcomes...
January 2018: Journal of Human Reproductive Sciences
https://www.readbyqxmd.com/read/29668890/luteinizing-hormone-facilitates-antral-follicular-maturation-and-survival-via-thecal-paracrine-signaling-in-cattle
#12
Katsushige Hattori, Makoto Orisaka, Shin Fukuda, Kimihisa Tajima, Yukiko Yamazaki, Tetsuya Mizutani, Yoshio Yoshida
The use of LH supplementation in assisted reproductive technology (ART) cycles improves the ongoing pregnancy rate in women with poor ovarian response (POR). However, our knowledge of the precise role of LH during the follicular phase of the menstrual cycle is incomplete. To explore the role of LH in the maturation of small antral follicles, we used an in vitro two-cell system that involved co-culturing bovine granulosa cells (GC) and theca cells (TC) on a collagen membrane. Treatment of TC with LH stimulated androgen production in TC by inducing the expression of androgenic factors, subsequently increasing estrogen biosynthesis in GC by providing androgen substrates and inducing aromatase expression...
April 13, 2018: Endocrinology
https://www.readbyqxmd.com/read/29664789/what-is-new-in-the-management-of-poor-ovarian-response-in-ivf
#13
Alberto Vaiarelli, Danilo Cimadomo, Nicolò Ubaldi, Laura Rienzi, Filippo Maria Ubaldi
PURPOSE OF REVIEW: The management and treatment of patients with poor ovarian response is still a controversial issue in IVF. Increasing evidences demonstrate that the number of oocytes retrieved after a controlled ovarian stimulation (COS) greatly influences the clinical outcome in terms of cumulative live birth per started cycle. For this reason, any COS should aim to optimize the number of oocytes according to the ovarian reserve of the patient. The aim of this review is to provide an overview of new strategies proposed to manage poor responders according to the novel POSEIDON classification...
June 2018: Current Opinion in Obstetrics & Gynecology
https://www.readbyqxmd.com/read/29663364/impact-of-iaspp-on-chemoresistance-through-plk1-and-autophagy-in-ovarian-clear-cell-carcinoma
#14
Ka-Kui Chan, Oscar Gee-Wan Wong, Esther Shuk-Ying Wong, Karen Kar-Loen Chan, Philip Pun-Ching Ip, Ka-Yu Tse, Annie Nga-Yin Cheung
Ovarian clear cell carcinoma (OCCC) is a type of epithelial ovarian cancer that is strongly associated with endometriosis, resistance against conventional chemotherapy and thus poorer prognosis. The expression of inhibitory member of the ASPP family proteins (iASPP) and Polo-like kinase (PLK)1 were significantly higher in OCCC compared to benign cystadenomas and endometriosis. Both protein expressions were found to correlate with chemoresistance in patients with OCCC while high iASPP expression alone was significantly associated with a poor patient survival...
April 16, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29662660/clinical-outcomes-of-women-with-ovarian-metastases-of-colorectal-cancer-treated-with-oophorectomy-with-respect-to-their-somatic-mutation-profiles
#15
Yoshiko Mori, Akihiro Nyuya, Kazuya Yasui, Toshiaki Toshima, Takashi Kawai, Fumitaka Taniguchi, Keisuke Kimura, Ryo Inada, Masahiko Nishizaki, Junko Haraga, Keiichiro Nakamura, Yuzo Umeda, Hiroyuki Kishimoto, Toshiyoshi Fujiwara, Yosuke Katata, Yoshiyuki Yamaguchi, Takeshi Nagasaka
We clarified the clinical prevalence of ovarian metastases from colorectal cancers (CRCs) in 296 female patients with CRC and evaluated clinical outcomes with relation to their mutational profiles, such as BRAF/KRAS mutation and microsatellite instability (MSI) status. The female CRCs were categorised into three subsets: CRCs with ovarian metastases [6.4% ( n = 19), 5-year overall survival (OS) = 24.7%], CRCs with extra-ovarian metastases only [32.4% ( n = 96), 5-year OS = 34.5%] and CRCs without any recurrence or metastasis [61...
March 27, 2018: Oncotarget
https://www.readbyqxmd.com/read/29661778/immunogenomic-analyses-of-advanced-serous-ovarian-cancer-reveal-immune-score-is-a-strong-prognostic-factor-and-an-indicator-of-chemo-sensitivity
#16
Li-Jun Di, Dapeng Hao, Jie Liu, Meng Chen, Jingjing Li, Li Wang, Guangyu Wang, Qi Zhao
PURPOSE: Ovarian cancer is one of the first human cancers for which in situ immune response was reported to be important for the clinical outcome. To elucidate the mechanistic relationship between immune repertoire and cancer genotype in ovarian cancer, the development of a well-defined immune score for ovarian cancer is required. EXPERIMENTAL DESIGN: From a collection of 2,203 patient samples of advanced ovarian cancer from public available resources, we evaluated the prognostic values for a compendium of immune marker genes and proposed an immune score...
April 16, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29645088/impact-of-iaspp-on-chemoresistance-through-plk1-and-autophagy-in-ovarian-clear-cell-carcinoma
#17
Ka-Kui Chan, Oscar Gee-Wan Wong, Esther Shuk-Ying Wong, Karen Kar-Loen Chan, Philip Pun-Ching Ip, Ka-Yu Tse, Annie Nga-Yin Cheung
Ovarian clear cell carcinoma (OCCC) is a type of epithelial ovarian cancer that is strongly associated with endometriosis, resistance against conventional chemotherapy and thus poorer prognosis. The expression of inhibitory member of the ASPP family proteins (iASPP) and Polo-like kinase (PLK)1 were significantly higher in OCCC compared to benign cystadenomas and endometriosis. Both protein expressions were found to correlate with chemoresistance in patients with OCCC while high iASPP expression alone was significantly associated with a poor patient survival...
April 12, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29644000/cdk4-6-inhibition-as-maintenance-and-combination-therapy-for-high-grade-serous-ovarian-cancer
#18
Mangala Iyengar, Patrick O'Hayer, Alex Cole, Tara Sebastian, Kun Yang, Lan Coffman, Ronald J Buckanovich
High grade serous ovarian cancer (HGSOC) is a disease with a high relapse rate and poor overall survival despite good initial responses to platinum-based therapy. Cell cycle inhibition with targeted CDK4/6 inhibitors is a new therapeutic approach showing promise as a maintenance therapy in cancer. As multiple genes in the CDK4/6 pathway are commonly mutated or dysregulated in ovarian cancer, we evaluated the efficacy of the CDK4/6 inhibitor Ribociclib alone, in combination with chemotherapy, and as maintenance therapy in several models of HGSOC...
March 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29643276/expression-of-placenta-growth-factor-is-associated-with-unfavorable-prognosis-of-advanced-stage-serous-ovarian-cancer
#19
Qin Meng, Pengjing Duan, Lin Li, Yongmei Miao
Ovarian cancer is the fourth leading cause of cancer death in women and the most fatal gynecologic malignancy. Placenta growth factor (PGF), a member of the vascular endothelial growth factor, plays an important role in angiogenesis. The overexpression of PGF was observed in several types of cancers, but the clinical significance of PGF in epithelial ovarian cancer (EOC) is still unknown. To explore the prognostic value of PGF among patients with serous EOC, we analyzed the expression of PGF in 89 EOC specimens by immunohistochemistry...
April 2018: Tohoku Journal of Experimental Medicine
https://www.readbyqxmd.com/read/29629954/ovarian-clear-cell-carcinoma-from-morphology-to-molecular-biology
#20
Giuseppina Improta, Angela Pettinato, Estrid Høgdall, Giuseppe Santeusanio, Simona Vatrano, Filippo Fraggetta, Gian Franco Zannoni
Ovarian clear cell carcinoma (oCCC) is a distinctive subtype of ovarian carcinoma, with peculiar genetic and environmental risk factors, precursor lesions, molecular events during oncogenesis, patterns of spread, and response to treatment. Because of low response to chemotherapy and poor prognosis in advanced stages, there is growing interest in investigating the molecular pathways involved in oCCC development, in order to individualize novel/molecular targeted therapies. Until now, the main molecular genetic changes associated with oCCC remain to be identified, and, although several molecular changes have been reported in clear cell tumors, most studies have analyzed a limited number of cases; therefore, the true prevalence of those changes is not known...
April 7, 2018: Applied Immunohistochemistry & Molecular Morphology: AIMM
keyword
keyword
57151
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"